Jibe builds universal immune cell engagers that redirect both the body's own antibodies and externally administered ones to activate immune cells against disease. Their platform enables a single therapeutic to harness existing antibody responses, potentially expanding treatment options without needing to develop new antibodies for each target.
Funding
Funding not disclosed
Founders
Product
Problem
Current antibody‑based immunotherapies often require the development of disease‑specific monoclonal antibodies, a process that is time‑consuming, costly, and limited by the need to generate new proteins for each target.
Solution
Jibe engineers universal immune cell engagers—modular protein scaffolds that bind to any endogenous or administered antibody and redirect it toward selected immune cell receptors. By leveraging the patient’s existing antibody repertoire or co‑administered antibodies, the platform activates novel immune pathways without the need to create bespoke antibodies for each indication. This approach streamlines manufacturing, reduces development timelines, and expands the applicability of antibody‑mediated immunotherapy across diverse disease areas.
Target Audience
Primary customers are pharmaceutical and biotech companies developing immunotherapies, as well as clinical researchers seeking to enhance antibody‑mediated mechanisms across oncology, infectious disease, and autoimmune indications.
Features
- Modular protein design that couples a generic antibody‑binding domain with customizable immune cell‑targeting motifs
- Compatibility with both endogenous antibodies and exogenous therapeutic antibodies
- Ability to engage multiple immune cell types (e.g., T cells, NK cells, macrophages) through interchangeable receptor ligands
- Scalable production using standard recombinant protein expression platforms
- Platform flexibility to address a broad range of indications without redesigning the antibody component